KarXT for Schizophrenia

Questions for Deliberation and Voting: February 9th, 2024 Public Meeting

These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.

*Patient Population for All Questions:* Adults with an established diagnosis of schizophrenia who are not considered to have treatment-resistant schizophrenia.

*Antipsychotic Therapy for All Questions:* Therapy is being used for *maintenance* treatment and the comparator therapy and other second-generation antipsychotic treatments are available as next-line treatments if the chosen therapy is ineffective or is discontinued for adverse effects.

**Clinical Evidence**

1. Is the currently available evidence adequate to demonstrate that the net health benefit of KarXT is superior to that of aripiprazole?

   Yes  No

2. Is the currently available evidence adequate to demonstrate that the net health benefit of KarXT is superior to that of olanzapine and/or risperidone?

   Yes  No
Contextual Considerations and Potential Other Benefits or Disadvantages

Please vote on the following contextual considerations:

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for schizophrenia, on the basis of the following contextual considerations:

1= Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5= Very high priority

3. Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability
4. Magnitude of the lifetime impact on individual patients of the condition being treated

Please vote on the following potential other benefits or disadvantages:

What are the relative effects of KarXT versus second generation antipsychotics on the following outcomes that inform judgment of the overall long-term value for money of KarXT?

1= Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

5. Patients’ ability to achieve major life goals related to education, work, or family life
6. Caregivers’ quality of life and/or ability to achieve major life goals related to education, work, or family life
7. Patients’ ability to manage and sustain treatment given the complexity of regimen
8. Society’s goal of reducing health inequities

Long-Term Value for Money

9. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at current pricing with KarXT versus aripiprazole?*
   a. Low long-term value for money at current prices
   b. Intermediate long-term value for money at current prices
   c. High long-term value for money at current prices

*This vote will only be taken if a price becomes available for KarXT.